Jul 29, 2019
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
May 07, 2019
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Apr 30, 2019
Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
Apr 09, 2019
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
Mar 13, 2019
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar 12, 2019
Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
Mar 06, 2019
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
Nov 13, 2018
Phase 2 Data for Galmed Pharmaceutical's Aramchol(TM) in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018
Nov 05, 2018
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
Oct 29, 2018
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
Oct 02, 2018
Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol(TM) to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®
Sep 27, 2018
Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
Aug 03, 2018
Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025
Aug 02, 2018
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
Jul 26, 2018
Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2
Jun 19, 2018
Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares
Jun 18, 2018
Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares
Jun 12, 2018
Galmed's 600 mg Aramchol(TM) Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study
Jun 11, 2018
Galmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study
May 09, 2018
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results